Craniospinal Irradiation in Histone AlteRed Midline Glioma
Recruiting
N/A
Interventional Study
Glioma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 3 – 18
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 32 (estimated)
- Sponsor
- Tata Memorial Centre · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Paediatric H3K27/H3G34 mutant diffuse midline gliomas are high grade gliomas that arise in midline structures/cerebral hemispheres and are known to have dismal outcomes. Standard treatment includes definitive radiation therapy to primary site along with concurrent temozolomide chemotherapy following histological confirmation with a biopsy. Studies have shown poorer outcomes in the paediatric age g…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Newly diagnosed biopsy proven histone altered diffuse midline glioma
2. Age- ≥3 to \<18 years at time of diagnosis
3. Karnofsky/Lansky Performance Score more than or equal to 70
4. Has provided written informed consent/ assent form
5. No prior therapy except debulking surgery…
Contacts